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Isolation 
Adapted from Nordmann P. et al., EID 18(9), Sept 2012 
Outcome 
Directed  
treatment 
Empirical  
treatment + 
BSIs 
Mean decrease in survival of 
7. 6% for each hour after the 
onset of BSI until initiation of 
effective antibiotics 
[Kumar A et al., Crit Care Med, 2006] 
Septic shock  
Inappropriate antibiotics within 
the first 6 hours is associated 
with a 5- fold higher mortality 
risk 
[Kumar A et al., Chest, 2009] 
Schieffer KM et al., J Appl Micro; 116, 2014 
Hoyos-Mallecotet al., J Micro Meth; 105, 2014 
MALDI-TOF MS 
Sepsityper extraction kit 
(Bruker Daltonics) 
~15 min  
(vs. 7-45 min for lab methods) 
~80-85% efficient extraction 
(vs. 85-90% for lab methods)  
 
Incl. those with score <1.6 
ID in ~1h 
Reduction of 6-83 hrs 
Ertapenem 
neg 
pos 
Generic activity in ~4.5 hrs 
Can be reduced to ~30 min-2 hrs 
~20 min 
n=411 +BCs 
19 carba producers (21 controls) 
Sens and Spec: 100% and 90% 
Jayol A. et al., J Clin Micro; 54:9, 2016 
Dortet L. et al., Emerg Infect Dis; 21:3, 2015 
Colorimetric tests 
NDP test 
Overall, ~30 min 
Sens/Spec: 100% 
Final results in 2-4 hrs 
Sens and Spec: 98% and 100% Preparation from +BCs: ~3 hrs 
Reaction in 5 min-1 h (max 2 hrs) 
Sens and Spec 98% and 100% 
Dortet L. et al., Clin Microbiol Inf; 20, 2014 
~10 Euro 
Antibiotics Mechanism Most frequent protein/genes 
Cephalosporins ESBLs CTX-Ms 
TEMs and SHVs (not all are ESBLs) 
PERs, VEBs, GESs, SFO, etc. 
Plasmidic AmpCs CMYs, DHAs 
FOXs, LATs, BILs, MOXs, MIRs, ACTs  
Chromos. AmpCs Promoter region (E. coli) 
AmpD (Enterobacter spp.) 
Carbapenems Carbapenemases Class A: - KPCs, GESs 
Class B:  - NDMs, VIMs, IMPs 
- SPMs, GIMs, AIMs, SIMs 
Class D:  - OXA-48 
- OXA-48-like 
- OXA-23, -24/40, -58 
Porins OmpK36 (K. pneumoniae) 
OmpF/OmpC (E. coli) 
OmpF/OmpC (E. cloacae) 
Quinolones QRDR Substitutions in GyrA and ParC 
PMQR determinants QnrA/B/S, QepA, aac(6)-Ib-cr 
Aminoglycosides AMEs aac(6)-I-like, ant(3)-like, aph(3)-like 
16S rRNA methyl. ArmA, RmtA/B/C/D/E, NpmA 
Polymyxins Plasmid mediated Mcr-1-/-2-like 
Chromosomal mgrB (K. pneumoniae) 
Fosfomycin Plasmid-mediated fos genes 
Gram-negatives 
Ideal system: 
• Species identification 
• Resistance mechanisms 
• Kit and automated (easy to use) 
• High sensitivity/specificity 
• Clinical samples (or at least +BCs) 
• Rapid  
• Cost-effective 
Antibiotics Mechanism Most frequent genes 
Β-lactams PBP2 mecA, mecAv, mecB, mecC 
β-lactamases blaZ 
Glycopeptides vanA, vanB, vanC/D/E/G/Z 
Quinolones QRDR Substitutions in GyrA and ParC 
Aminoglycosides AMEs aac(6)-I-like, aph(2)-I-like….. 
Macrolides 
ermA/B/C, msr, mefA/E, ereA/B…  
Clindamycin 
Lincosamides lnuA-D, lsaB-E 
Streptogramins vat, vga, vgb genes 
Linezolid cfr 
Mupirocin mupR 
Phenicols cat genes, fexA 
Trimethoprim Folate inhibitors dfrA, dfrD, dfrG, dfrK 
Tetracyclines tetK, tetL, tetM/O/Q/S…….  
Fusidic acid fusB, fusC, fusD 
Gram-positives 
Check-Direct Screening, Check-Points 
• Rapid preparation  
• Time to results (<3 hrs) 
KPC 
OXA-48-like 
VIM 
NDM 
CTX-M-1 group 
CTX-M-2 group 
CTX-M-9 group 
SHV-ESBL 
Rectal  
swab 
(Copan, ESwab) 
BD MAX Reagent strip 
~30 Euro 
Antonelli et al., DMID, 2016 
Limit of detection (LOD) 
Florence, Italy 
557 rectal swabs 
Summary of the results  
Performance of Check-Direct CPE screening for BD MAX  
ChromID CARBA SMART (w/wo broth enrichment) 
[5 samples not detected] 
23 KPC 
5 VIM 
1 OXA-48 
TAT from 18-24 hrs (direct culture)  
or 48 hrs (broth enrichment) to 3 hrs 
Culture vs.  C-D direct CPE (2 ≠ master mix) 
18 (3%) unresolved 
6 (1%) unresolved 
Cepheid GeneXpert 
Real-time multiplex PCR 
- Smart fluidic system 
- Filtering and Sonication (DNA) 
- Fluorescent-labeled hybr. probes (6 colors)  
- Internal control 
KPC 
NDM 
OXA-48-like 
VIM 
IMP-1 
MSSA 
MRSA 
CoNS 
 
spa, mecA 
SCCmec-orfX  
• Add aliquot to elution, vortex, transfer to port S 
• Insert cartridge to station (overall, 1 min) 
• Run time (<1 h) 
~50 Euro 
JCM, 54:7; 2016 
4 centers (2 USA, 1 UK, 1 Spain) 
July 2013 – Feb 2014 
633 samples 
Results (obtained in 32-48 min) Results by individual targets 
Performance vs. reference method Performance for different targets 
23.5% 
Sensitivity: 96.6% 
Specificity: 98.6% 
50% of them spiked at 1.1 x 102 to 1.2 x 103 CFU/swab (LOD of Xpert) 
6 out of 154 specimens not detected by Xpert 
6 cases of multiple genes (4 not detected by ref. method) 
Buchan BW et al., J Clin Microb, 53:3; 2015 
Identification of Staphylococcus aureus 
Identification of MRSA 
Multicenter study (8 hospitals, USA) 
795 BCs (30%, S. aureus; 13% MRSA) 
Initial test validity 
 - Xpert: 96.1% 
 - GeneOhm: 96.3% 
Retest:  
 - Xpert: 99.6% 
 - GeneOhm: 98.1% 
 
Statistically equivalent 
Statistically equivalent 
Verigene, Nanosphere 
• Load cartridge, consumables, and sample (5 min) 
• Automated sample preparation and processing 
• Place slide from cartridge in reader (2.5 hrs) 
Gram-negatives cartridge Gram-positives cartridge 
Microarray approach by 
using Au-nanoprobe as 
reporter and silver 
reduction to enhance signal 
~50 Euro 
Gilman K.H. Siu et al., Plos One, Oct 2015 
ID for Gram-positives (agreement 89.6%) ID for Gram-negatives (agreement 90.5%) 
Multicenter study (4 hospitals) 
364 BCs (114 Gram-pos; 250 Gram-neg) 
Jan 2014 – May 2014 
Drug-Resistant Organisms Time to Results (40-99 hrs faster than routine) 
Initial test validity: 95.6% 
A. hydrophila, M. morganii, Salmonella spp., A. faecalis, B. pseudomallei, H. influenzae, R. 
planticola, P. putida, S. maltophilia not detectable with the system (n=16; 5.5%) 
K. variicola 80% 
Walker T. et al., J Clin Microbiol; 54:7, 2016 
6-month period before Verigene (n=98) vs. 6-month period after Verigene (n=97) 
Factors associated to length of ICU stay 
Clinical outcome 
Multiv. log. regression for association with 30-d mortality   
Los Angeles 
May 2013 - Nov 2013 
Dec 2014 – May 2015 
Saved 11,661 USD/case 
• Preparation of the pouch  
• Add pouch to FilmArray station (overall, 2 min) 
• Run time of about 1 h 
Pouch (polypropylene) 
Pneumatic system 
Multiplex PCR 
(RT-PCR for RNA target) 
Multiplex real-time PCR  
and Melting analysis 
~100 Euro 
BioFire FilmArray 
Magnetic beads 
Salimnia H.. et al., J Clin Microbiol; 54:3, 2016 
Drug-Resistant 
Organisms 
Species ID 
 
8 centers in USA 
July 2012 - Feb 2014 
2,207 BC samples 
 - 1,568 clinical 
 - 639 seeded 
FilmArray performed: 
 - BC+, within 8 hrs 
  - 52% clinical samples 
  - 66% seeded cultures 
 - Aliquot frozen (<8 hrs) 
Only 1.9% needed repeat testing 
R. ornithinolytica 98% 
Intervention group (FilmArray) 
(Aug 2013 – Jan 2014; n=84)  
vs.  
Historical control group  
(Jan 2012 – Jun 2013; n=252) 
Gainesville, Florida 
Pardo J et al., DMID; 84, 2016 
Time to discharge after 
CoNS-contaminated BCs 
Unnecessary vancomycin use 
129 USD 
55% CoNS 
Amplex Eazyplex 
• Preparation (5 min) 
• No DNA extraction 
• Run time (<30 min) 
Version A Version B 
LAMP 
Loop-mediated isothermal Amplification 
 
Real-time fluorescent measurement 
Genie II platform 
~55 Euro 
Hinic V. et al., J Microb Meth; 119, 2015 
50 urine samples 
 
33 ESBL+ and/or carbapenemases 
- Vitek 2 and Etest ESBL/AmpC strips 
- Eazyplex on colonies 
LOD in Urine 
First run with 50 urines: 
 - 2 invalid results 
 - 1 false-positive NDM (19 min) 
Avg. 8 min 
Sensitivity: 100% 
Specificity: 97.9% 
Rödel J. et al., Eur J Clin Microbiol Infect Dis; Jan 2017 
ID § 
Resistance 
In-house LAMP assays (not available) 
Time to 
results 
Jena, Germany 
April to Aug 2015 
370 BCs + (of which 140 G+) 
In principle, from +BC ~30 min 
Curetis Unyvero 
• Sample transferred to Unyvero tube (2 min) 
• Lysis (30 min), transfer to cartridge, plus master mix (3 min) 
• Overall, time to results (~5 hrs) 
* Mycobacterium spp.; Fungi 
Pneumonia panel (P55) Blood culture panel (BCU) 
DNA purification, PCR set up, multiplex PCRs with array detection 
Personne Y. et al., DMID; 86: 2017 
London, UK (two hospitals) 
Dec 2014 – June 2015 
Pneumonia 
(42% in ICU) 
Routine 
5.5% polymicrobial 
Unyvero 
49% polymicrobial 
 
It is not a 
quantitative test 
Sens/Spec: 96% and 33% 
Species ID 
Detection of ARGs 
Routine 
36% of strains fully susceptible 
60% resistant to ≥ 1 antibiotic 
40% were MDR 
Unyvero 
71% of samples with ≥1 ARG 
(e.g., blaTEM, ermB, sul1) 
Highly prevalent in commensals 
50 sputa 
32 ETT aspirates 
3 BAL 
Avg. pathogens  0.59 vs. 1.59  
Abbott IRIDICA PCR-ESI MS system 
KPC, VanA, VanB, mecA 
5 mL 
100 µL for  
LRT samples 
Ibis T5000, Abbott PLEX-ID 
Metzgar D. et al.,  
PlosOne; July 2016 
Species ID 
Antibiotic R markers 
Johns Hopkins Hospital; Baltimore, USA 
285 whole blood samples (with SIRS) 
Samples processed by Ibis Bioscience 
Limit of detection (LOD) in blood:  
S. aureus,  32 CFU/mL; E. faecium 16 CFU/mL; K. pneumoniae 32 CFU/mL  
273 (95.7%) valid results 
61 negative controls: all negative by IRIDICA 
Organisms detected: IRIDICA, n=85; culture, n=45 
32 out of 40 by culture (80% agreement) 
Excluding contaminants 30/35 (86% agreement)  
11 of these 46 pathogens gave subsequent infection 
13/13 
Ullberg M. et al., PlosOne; Jan 2017 
Karolinska University Hospital, Sweden 
121 BAL samples 
May 2014 – March 2015 
Pathogenic species Routine: 104+/121 (86%) 
IRIDICA: 118+/121 (98%) 
245 organisms:  
 18 species 
 42 species 
Not detected  
by routine culture 
(but other methods) 
15 by routine culture 
2 by routine culture 
Detection of resistance determinants 
 - mecA in 21/121 (17%), but only 8/21 were also positive for S. aureus 
 - MRSA not detected by culture and only 1 S. aureus had growth 
 - No BAL with vanA/B or blaKPC 
Mostly 
CoNS+ 
Schmidt K. et al., JAC; 72: 2017 
Species ID 
ARGs (vs. MICs/EUCAST and Illumina HiSeq) 
Norfolk/Norwich Hospitals, UK 
10 urines (>107 CFU/mL) and 5 spiked (MDR-Ec) 
MinION: rapid, low capital cost, small  
4-10 mL urine 
Initially, BLAST and CARD databases 
WIMP Metrichor application  
Metrichor’s ARMA 
In all cases, MinION 
correctly identified 
the pathogen  
(WIMP in 15 min) 
7-8 hrs 
(~4 hrs) 
Illumina detected 55 ARGs from cultured strains. MinION detected 51 of them. 
But, allelic variants poorly distinguished (e.g., mutations in gyrA/parC; cAmpCs and pAmpCs) 
500 Euro/cell 
7x coverage 
(99% genome) 
Species identification 
 
 
 
Resistance mechanisms 
 
 
 
 
 
 
 
Kit and automated 
 
High sensitivity/specificity 
 
 
 
Clinical samples 
 
 
 
 
Rapid (TAT)  
 
 
Cost-effective 
Conclusions 
- Some systems do not provide species ID 
For rectal swabs ID probably not necessary 
- Only some report many species [Verigene, FilmArray, Unyvero, Iridica, MinION] 
- Most systems have a limited list of ARGs (e.g., only KPC) 
- Only some report many ARGs [Verigene, Unyvero, MinION] 
- Inability to detect new/emerging ARGs 
- Inability to recognize variants (e.g., cAmpCs vs. pAmpCs) 
- Is the detected ARG expressed? 
- Only two link the ARG with the species ID [Xpert, MinION] 
- Almost all are relatively easy to use (from samples to results) 
- In general they have good sensitivity (but LOD < than culture)  
- Specificity is low for non-sterile specimens (e.g., from LRT) 
Difficult interpretation (what will we tell to clinicians?) 
- Most systems are used for rectal swabs or positive BCs 
- Only IRIDICA for whole blood 
- “Not ready” for direct implementation in respiratory samples 
- From <1 h [colorim., Xpert, FilmArray, Eazyplex] to 4-8 h [Unyvero, Iridica, MinION]  
- The overall outcome is affected in positive (but lack of studies) 
- From ~10 Euro [e.g., colorimetric] to ~600 Euro [e.g., MinION] 
- Who pay? Still difficult to convince institutions    
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